A phase 3 trial comparing ixekizumab with placebo and etanercept for moderate-to-severe plaque psoriasis: Results from the 12 week induction period of UNCOVER 3

被引：0

作者：

Griffiths, Christopher E. ^{[1
]}

Reich, Kristian ^{[2
]}

Lebwohl, Mark ^{[3
]}

Van de Kerkhof, Peter ^{[4
]}

Paul, Carle ^{[5
]}

Menter, Alan ^{[6
]}

Carlier, Hilde ^{[7
]}

Cameron, Gregory ^{[7
]}

Erickson, Janelle ^{[7
]}

Zhang, Lu ^{[7
]}

Secrest, Roberta ^{[7
]}

Ball, Susan ^{[7
]}

Braun, Daniel ^{[7
]}

Osuntokun, Olawale ^{[7
]}

Heffernan, Michael ^{[7
]}

Nickoloff, Brian ^{[7
]}

Papp, Kim ^{[8
]}

机构：

[1] Univ Manchester, Inst Inflammat & Repair, Manchester, Lancs, England

[2] Dermatologickum Hamburg, Hamburg, Germany

[3] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA

[4] Radboud Univ Nijmegen, Dept Dermatol, NL-6525 ED Nijmegen, Netherlands

[5] Univ Toulouse 3, Dept Dermatol, F-31062 Toulouse, France

[6] Univ Texas SW Med Ctr Dallas, SW Med Sch, Dallas, TX 75390 USA

[7] Eli Lilly & Co, Indianapolis, IN 46285 USA

[8] Prob Med Res, Waterloo, ON, Canada

来源：

JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2015年 / 135卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P059

引用

页码：S17 / S17

页数：1

共 50 条

[1] A phase 3 trial comparing ixekizumab with placebo and etanercept for moderate-to-severe plaque psoriasis: Results from the 12 week induction period of UNCOVER-2
Griffiths, Christopher E.
Reich, Kristian
Lebwohl, Mark
Van de Kerkhof, Peter
Paul, Carle
Menter, Alan
Carlier, Hilde
Cameron, Gregory
Erickson, Janelle
Zhang, Lu
Secrest, Roberta
Ball, Susan
Braun, Daniel
Osuntokun, Olawale
Heffernan, Michael
Nickoloff, Brian
Papp, Kim
[J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S17 - S17
[2] A Phase 3 Trial Comparing Ixekizumab with Placebo and Etanercept for Moderate-to-Severe Plaque Psoriasis: Results from the 12 Week Induction Period of UNCOVER-2
Griffiths, C. E. M.
Leutz, A.
Reich, K.
Lebwohl, M.
van de Kerkhof, P.
Paul, C.
Menter, A.
Cameron, G. S.
Erickson, J.
Zhang, L.
Secrest, R.
Ball, S.
Braun, D.
Osuntokun, O. O.
Heffernan, M.
Nickoloff, B. J.
Papp, K.
[J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 3 - 3
[3] Ixekizumab impact on itch severity compared to etanercept and placebo: Results from UNCOVER-2, a phase 3 trial in patients with moderate-to-severe plaque psoriasis
Kimball, Alexa Boer
Nikai, Enkeleida
Zhu, Baojin
Carlier, Hilde
Yosipovitch, Gil
[J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S19 - S19
[4] Ixekizumab for treatment of moderate-to-severe plaque psoriasis: 12-week results from a phase 3 study (UNCOVER-1)
Gordon, Kenneth
Blauvelt, Andrew
Langley, Richard
Luger, Thomas
Ohtsuki, Mamitaro
Cameron, Gregory S.
Braun, Daniel K.
Erickson, Janelle
Zhao, Fangyi
Shrom, David S.
Osuntokun, Olawale O.
Heffernan, Michael P.
Nickoloff, Brian
Leonardi, Craig
[J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S6 - S6
[5] Efficacy and safety of ixekizumab compared to etanercept or placebo treatment of patients with moderate-to-severe plaque psoriasis and palmoplantar involvement over a 60-week dosing period: results from UNCOVER-3, a Phase 3 trial
Warren, R. B.
Morita, A.
Menter, A.
Duffin, K. Callis
Langley, R.
Amato, D.
Dennehy, E. B.
Kerr, L. N.
Shrom, D.
Reich, K.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 78 - 79
[6] Maintenance of Efficacy Results from UNCOVER-1: A Phase 3 Trial of Ixekizumab for Moderate-to-Severe Plaque Psoriasis
Leonardi, C.
Leutz, A.
Blauvelt, A.
Langley, R. G.
Luger, T.
Ohtsuki, M.
Cameron, G. S.
Erickson, J.
Zhao, F.
Shrom, D. S.
Braun, D.
Osuntokun, O. O.
Heffernan, M.
Nickoloff, B. J.
Gordon, K.
[J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 4 - 4
[7] Maintenance of efficacy results from UNCOVER-1: A phase 3 trial of ixekizumab for moderate-to-severe plaque psoriasis
Leonardi, Craig
Blauvelt, Andrew
Langley, Richard
Luger, Thomas
Ohtsuki, Mamitaro
Cameron, Gregory S.
Braun, Daniel
Erickson, Janelle
Zhao, Fangyi
Shrorn, David S.
Osuntokun, Olawale O.
Heffernan, Michael P.
Nickoloff, Brian
Gordon, Kenneth
[J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S16 - S16
[8] Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Griffiths, Christopher E. M.
Reich, Kristian
Lebwohl, Mark
van de Kerkhof, Peter
Paul, Carle
Menter, Alan
Cameron, Gregory S.
Erickson, Janelle
Zhang, Lu
Secrest, Roberta J.
Ball, Susan
Braun, Daniel K.
Osuntokun, Olawale O.
Heffernan, Michael P.
Nickoloff, Brian J.
Papp, Kim
[J]. LANCET, 2015, 386 (9993): : 541 - 551
[9] Ixekizumab impact on health-related quality of life compared to etanercept and placebo: Results from UNCOVER-2, a phase 3 trial in patients with moderate-to-severe plaque psoriasis
Reich, Kristian
Toth, Darryl
Nikai, Enkeleida
Zhu, Baojin
Carlier, Hilde
Feldman, Steven
[J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S35 - S35
[10] Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
Gordon, K. B.
Blauvelt, A.
Papp, K. A.
Langley, R. G.
Luger, T.
Ohtsuki, M.
Reich, K.
Amato, D.
Ball, S. G.
Braun, D. K.
Cameron, G. S.
Erickson, J.
Konrad, R. J.
Muram, T. M.
Nickoloff, B. J.
Osuntokun, O. O.
Secrest, R. J.
Zhao, F.
Mallbris, L.
Leonardi, C. L.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (04): : 345 - 356

← 1 2 3 4 5 →